An impurity of Eptifibatide. Eptifibatide, is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called RGD (arginine-glycine-aspartate)-mimetics and reversibly binds to platelets.
CAT No: 10-101-203
Eptifibatide Impurity 3 is a peptide-based research compound structurally related to the parent molecule eptifibatide, a cyclic heptapeptide known for its integrin receptor inhibition properties. As an identified process impurity or degradation product, Eptifibatide Impurity 3 is of significant interest in the context of pharmaceutical development, peptide synthesis quality control, and analytical method validation. Its presence and characterization are critical for ensuring the safety, efficacy, and regulatory compliance of peptide-based drug substances, particularly those targeting platelet aggregation pathways. The compound's unique peptide sequence and structural features make it a valuable analytical reference for laboratories engaged in the development and quality assessment of eptifibatide and similar glycoprotein IIb/IIIa antagonists.
Analytical method development: Eptifibatide Impurity 3 serves as a crucial reference standard for the development and validation of chromatographic and spectrometric methods used to analyze peptide drug substances. Its well-characterized structure enables researchers to optimize separation techniques such as HPLC or LC-MS, facilitating the accurate detection, quantification, and differentiation of impurities within complex peptide formulations. The availability of this impurity supports laboratories in establishing robust, reproducible analytical protocols that are essential for regulatory submissions and ongoing quality control.
Impurity profiling and stability studies: The compound plays an essential role in impurity profiling during the manufacturing and storage of eptifibatide. By incorporating Eptifibatide Impurity 3 into forced degradation and stability studies, scientists can monitor the formation and behavior of process-related byproducts under various conditions. This information is critical for understanding the degradation pathways of peptide therapeutics, assessing the stability-indicating capacity of analytical methods, and defining appropriate storage and handling requirements for peptide drug products.
Peptide synthesis optimization: In the context of synthetic peptide manufacturing, Eptifibatide Impurity 3 provides valuable insights into the efficiency and selectivity of peptide coupling and cyclization reactions. Its identification and quantification allow process chemists to pinpoint specific steps in the synthetic route that may give rise to side products or incomplete reactions. By studying the formation of this impurity, manufacturers can refine reaction conditions, improve overall yield and purity, and minimize the generation of unwanted byproducts during large-scale peptide synthesis.
Reference material for regulatory compliance: The use of well-characterized impurities such as Eptifibatide Impurity 3 is vital for meeting regulatory expectations regarding impurity identification and quantification in peptide pharmaceuticals. Laboratories can employ this compound as a reference material to demonstrate the specificity, sensitivity, and accuracy of analytical methods described in regulatory filings. Its inclusion in impurity panels supports comprehensive risk assessments and facilitates compliance with international guidelines governing the safety and quality of peptide-based therapeutics.
Structure-activity relationship (SAR) studies: Eptifibatide Impurity 3, due to its structural similarity to the active pharmaceutical ingredient, can be utilized in exploratory studies aimed at elucidating the relationship between peptide structure and biological function. Researchers investigating the binding affinity, receptor selectivity, or metabolic stability of glycoprotein IIb/IIIa antagonists may include this impurity in comparative assays to better understand how minor sequence or conformational changes influence peptide behavior. Such studies contribute to the rational design and optimization of next-generation peptide therapeutics and analogs.
1. Cationic cell-penetrating peptides are potent furin inhibitors
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
3. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More